USP37 Antibody

What is USP37 and what cellular functions does it regulate?

USP37 is a deubiquitinase enzyme (also known as ubiquitin carboxyl-terminal hydrolase 37 or deubiquitinating enzyme 37) with a molecular weight of approximately 110.2 kilodaltons. The protein plays multiple critical roles in cellular processes through its ability to remove ubiquitin from target proteins, thus preventing their degradation via the proteasome pathway. USP37 functions across several critical cellular mechanisms that are essential for genomic stability and cell cycle progression.

USP37's primary functions include:

• Cell cycle regulation through deubiquitination of cyclin-A (CCNA1 and CCNA2) during G1/S transition

• DNA replication regulation by stabilizing the licensing factor CDT1

• DNA damage response maintenance through deubiquitination and stabilization of checkpoint kinase 1 (CHK1)

• Enhancement of cell migration via deubiquitination of SNAI transcription factor

• Regulation of mitotic spindle assembly and progression through stabilization of chromatin-associated WAPL

USP37 exhibits substrate specificity for 'Lys-11'-linked polyubiquitin chains, a linkage type commonly generated by the anaphase-promoting complex/cyclosome (APC/C). This specificity is particularly important during cell cycle progression, as USP37 antagonizes APC/C activities at specific cell cycle checkpoints.

What applications are USP37 antibodies commonly used for in research?

USP37 antibodies are employed across multiple research applications with varying specificities and sensitivities depending on experimental requirements. Based on commercial availability and validated protocols, researchers typically utilize USP37 antibodies in the following applications:

When selecting antibodies for these applications, researchers should carefully evaluate validation data provided by manufacturers, including positive controls and specificity testing against related deubiquitinases. Cross-reactivity potential should be assessed, particularly when studying USP37 in non-human species due to sequence homology considerations.

How do I select the appropriate USP37 antibody for my specific research needs?

Selecting the appropriate USP37 antibody requires careful consideration of multiple factors to ensure experimental success. Start by defining your experimental goals, target species, and application requirements before evaluating the following criteria:

• Immunogen design: Determine which domain of USP37 the antibody was raised against. Antibodies targeting the N-terminus (aa 1-300) may detect different functional aspects compared to those targeting the C-terminus (aa 900 to C-terminus). This is particularly important if studying specific isoforms or truncated variants.

• Species reactivity: Confirm the antibody's validated reactivity with your species of interest. While many USP37 antibodies are validated for human samples, cross-reactivity with mouse, rat, or other species varies significantly.

• Application validation: Verify that the antibody has been validated for your specific application with supporting data (Western blot images, IHC sections, etc.).

• Clonality consideration:

  • Polyclonal antibodies offer broader epitope recognition but may have batch-to-batch variation

  • Monoclonal antibodies provide higher specificity for a single epitope but may be less robust to protein denaturation

• Post-translational modification detection: If studying phosphorylated USP37 (particularly at Ser-628, which enhances its activity), ensure the selected antibody does not have its epitope masked by this modification.

• Citation history: Prioritize antibodies with proven performance in peer-reviewed publications addressing similar research questions.

For highest reproducibility in long-term studies, select antibodies from manufacturers that provide detailed validation data including positive controls, knockout/knockdown validation, and specificity testing.

How does USP37 phosphorylation impact its deubiquitinase activity in cell cycle regulation?

USP37 activity is tightly regulated by phosphorylation during cell cycle progression, with significant implications for experimental design and data interpretation. Phosphorylation at serine-628 (Ser-628) represents a critical regulatory mechanism that maximizes USP37's deubiquitinase activity specifically during the G1/S transition.

The phosphorylation-dependent activation mechanism involves:

• CDK2-mediated phosphorylation: During late G1 and S phase, cyclin-dependent kinase 2 (CDK2) phosphorylates USP37 at Ser-628, which enhances its catalytic activity.

• Substrate specificity alteration: Phosphorylated USP37 demonstrates increased efficiency in deubiquitinating 'Lys-11'-linked polyubiquitin chains, which are predominantly assembled by the APC/C complex.

• Temporal regulation: This phosphorylation creates a feedback loop, as USP37 subsequently stabilizes cyclin-A (CCNA1 and CCNA2) through deubiquitination, preventing their premature degradation and promoting S phase entry.

When designing experiments to study USP37 activity, researchers must consider the phosphorylation state of the protein. Cell synchronization techniques should be employed to ensure consistent phosphorylation status across experimental samples. Additionally, phospho-specific antibodies can be utilized to distinguish between phosphorylated and non-phosphorylated forms of USP37.

For in vitro deubiquitinase assays, recombinant USP37 may lack proper phosphorylation, potentially underrepresenting its physiological activity. Researchers should consider using phosphomimetic mutations (S628D or S628E) or in vitro phosphorylation with purified CDK2 to more accurately reproduce the protein's native activity state.

What experimental approaches are most effective for studying USP37's role in DNA damage response pathways?

Investigating USP37's function in DNA damage response (DDR) pathways requires multifaceted experimental approaches that capture both its biochemical activity and cellular impact. USP37 has been shown to deubiquitinate and stabilize critical DDR components, including the ATP-dependent DNA helicase BLM, following DNA double-strand breaks (DSBs).

Effective experimental strategies include:

• DNA damage induction methods:

  • Radiomimetic drugs (e.g., bleomycin, neocarzinostatin) for DSB generation

  • UV irradiation for pyrimidine dimer formation

  • Hydroxyurea for replication stress induction

• Protein-protein interaction analyses:

  • Co-immunoprecipitation of USP37 with BLM or CHK1 before and after damage

  • Proximity ligation assays to visualize interactions in situ

  • FRET/BRET approaches for real-time interaction monitoring

• Functional assays for USP37 activity:

  • In vitro deubiquitination assays using purified components

  • Cell-based ubiquitin chain restriction analysis

  • Cycloheximide chase experiments to measure target protein stability

• Genetic manipulation approaches:

  • CRISPR/Cas9-mediated knockout or catalytic-dead mutants

  • Phospho-mutants (S→A) to prevent ATM-mediated phosphorylation

  • Domain-specific deletions to identify interaction regions

A particularly robust experimental workflow involves synchronized cell populations exposed to DNA damaging agents, followed by assessment of USP37's localization to damage sites (using immunofluorescence), quantification of its interaction with DDR components (co-IP), and measurement of target protein stability and ubiquitination status (Western blotting with ubiquitin antibodies).

For accurate interpretation, experiments should include controls for ATM inhibition, as ATM-mediated phosphorylation of USP37 enhances its binding to BLM following DNA damage. Time-course experiments are essential, as USP37's role may vary during different phases of the DDR.

What are the challenges in immunodetection of USP37 in different tissue types and how can they be overcome?

Immunodetection of USP37 across diverse tissue types presents several technical challenges that require optimization strategies for reliable results. These challenges stem from USP37's expression patterns, protein characteristics, and potential epitope masking issues.

Common challenges and their solutions:

• Variable expression levels:

  • Challenge: USP37 expression varies significantly across tissue types, with certain tissues exhibiting only low baseline expression.

  • Solution: Implement signal amplification methods such as tyramide signal amplification (TSA) for IHC or use high-sensitivity detection systems for Western blotting. For IHC applications, extend primary antibody incubation to overnight at 4°C.

• Epitope accessibility:

  • Challenge: The USP37 epitope may be masked by protein-protein interactions or conformational states in certain tissue contexts.

  • Solution: Optimize antigen retrieval methods; heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is generally effective, but some tissues may require more stringent conditions such as Tris-EDTA (pH 9.0) or enzymatic retrieval.

• Post-translational modifications:

  • Challenge: Phosphorylation (particularly at Ser-628) may alter antibody binding efficiency.

  • Solution: Select antibodies with epitopes not affected by known PTMs, or use multiple antibodies targeting different regions of USP37.

• Cross-reactivity concerns:

  • Challenge: Antibodies may cross-react with other deubiquitinating enzymes with structural similarities.

  • Solution: Validate specificity using knockdown/knockout controls specific to each tissue type being studied.

• Tissue-specific fixation effects:

  • Challenge: Different tissue types respond differently to fixatives, affecting epitope preservation.

  • Solution: Optimize fixation protocols by tissue type; shorter fixation times (4-12 hours) with 10% neutral buffered formalin are generally recommended for USP37 detection.

For immunohistochemistry applications specifically, researchers have reported success with a 1:250 dilution of USP37 antibodies in formalin-fixed, paraffin-embedded human ovarian carcinoma tissues using DAB detection following epitope retrieval, though optimal conditions may vary by tissue type.

How should experiments be designed to differentiate USP37's specific functions from other deubiquitinating enzymes?

Distinguishing USP37's specific functions from other deubiquitinating enzymes (DUBs) requires careful experimental design that accounts for functional redundancy, substrate overlap, and context-dependent activities. A comprehensive approach incorporating multiple complementary techniques yields the most reliable results.

Recommended experimental strategies:

• Genetic manipulation approaches:

  • Generate USP37-specific knockout or knockdown models

  • Create catalytic-dead mutants (C350S) that maintain protein interactions but lack enzymatic activity

  • Employ rescue experiments with wild-type vs. mutant USP37 to confirm specificity

• Substrate specificity analysis:

  • Perform in vitro deubiquitination assays with synthetic Lys11-linked versus Lys48/Lys63-linked polyubiquitin chains

  • Conduct comparative ubiquitinome profiling following USP37 depletion versus depletion of related DUBs

  • Analyze ubiquitination status of putative substrates (cyclin-A, CDT1, CHK1, BLM) after manipulation of USP37 versus other DUBs

• Biochemical differentiation techniques:

  • Use activity-based probes specific for DUB family subsets

  • Perform selective inhibition studies with available small molecule inhibitors

  • Analyze cell cycle-dependent activity patterns, as USP37's activity is distinctly regulated during G1/S transition

• Domain-specific interaction mapping:

  • Identify unique protein-protein interaction networks using BioID or APEX proximity labeling

  • Map binding domains that distinguish USP37 from other DUBs

  • Perform domain swap experiments to identify functional determinants

For robust data interpretation, include appropriate controls addressing:

• Potential compensatory upregulation of related DUBs following USP37 manipulation

• Cell cycle synchronization to capture USP37's phase-specific activities

• Validation in multiple cell types to distinguish context-dependent versus general functions

A particularly informative approach combines selective depletion of USP37 with cell cycle synchronization and subsequent analysis of substrate stability and ubiquitination status across the cell cycle, as this highlights USP37's unique temporal regulation compared to other DUBs.

What are the critical controls needed when validating USP37 antibody specificity?

Essential controls for USP37 antibody validation:

• Genetic depletion controls:

  • CRISPR/Cas9 knockout of USP37: Complete absence of signal confirms specificity

  • siRNA/shRNA knockdown: Proportional reduction in signal intensity validates specificity

  • Overexpression: Increased signal intensity at the expected molecular weight (110.2 kDa)

• Peptide competition assays:

  • Pre-incubation of antibody with immunizing peptide should abolish specific signal

  • Non-related peptide pre-incubation should not affect signal intensity

  • Dose-dependent competition provides additional validation

• Multiple antibody validation:

  • Compare results using antibodies targeting different epitopes (N-terminal vs. C-terminal)

  • Consistent results across antibodies from different suppliers or host species strengthen validation

  • Discrepancies may indicate isoform-specific detection or post-translational modifications

• Species cross-reactivity assessment:

  • Test antibody against recombinant USP37 from multiple species

  • Validate in cell lines from different organisms if cross-species applications are planned

  • Consider sequence homology when interpreting cross-species results

• Application-specific controls:

  • For Western blot: Include molecular weight markers and positive control lysates

  • For IHC/ICC: Include tissue/cells known to express or lack USP37

  • For IP: Include isotype control antibodies and beads-only controls

• Specificity panel testing:

  • Test against related DUBs, particularly USP family members with structural similarity

  • Evaluate potential cross-reactivity with proteins of similar molecular weight

When publishing results, researchers should document which validation controls were performed and include representative images demonstrating antibody specificity. This transparency enhances result interpretation and experimental reproducibility.

How can researchers effectively establish USP37's contribution to tumor progression in cancer models?

Establishing USP37's specific contribution to tumor progression requires a multifaceted approach spanning in vitro cellular models to in vivo tumor systems. USP37's roles in cell cycle regulation, DNA damage response, and epithelial-mesenchymal transition (EMT) suggest potential oncogenic functions that demand careful experimental investigation.

Comprehensive experimental framework:

• Expression correlation studies:

  • Analyze USP37 expression levels across tumor databases (TCGA, ICGC)

  • Perform tissue microarray immunohistochemistry comparing normal vs. tumor tissues

  • Correlate expression with clinical parameters (stage, grade, patient survival)

  • Stratify analysis by cancer subtypes to identify context-specific relevance

• Functional characterization in cell models:

  • Manipulate USP37 levels (overexpression, knockdown, knockout) in relevant cancer cell lines

  • Assess hallmark cancer phenotypes:

    • Proliferation (growth curves, EdU incorporation)

    • Apoptosis resistance (Annexin V staining, caspase activation)

    • Migration/invasion (transwell assays, wound healing)

    • Colony formation and anchorage-independent growth

  • Analyze pathway activation states following USP37 manipulation

• Mechanistic dissection:

  • Identify cancer-relevant substrates using ubiquitinome profiling

  • Perform rescue experiments with specific substrates (e.g., SNAI for EMT phenotypes)

  • Analyze ubiquitination status of key oncogenes and tumor suppressors

  • Explore synthetic lethality with DNA damage response pathways

• In vivo tumor models:

  • Generate xenograft models with USP37-manipulated cancer cells

  • Develop inducible USP37 transgenic or knockout mouse models

  • Assess tumor initiation, growth kinetics, and metastatic potential

  • Evaluate therapeutic response in USP37-high versus USP37-low tumors

• Therapeutic targeting assessment:

  • Test sensitivity to cell cycle inhibitors in USP37-high versus USP37-low conditions

  • Evaluate synergy with DNA damaging agents based on USP37's role in DNA damage response

  • Explore the development of USP37-specific inhibitors

For robust data interpretation, experiments should control for:

• Cell cycle status, as USP37's function is cell cycle-dependent

• Tissue context, as USP37's role may vary between cancer types

• Redundancy with other DUBs that might compensate for USP37 manipulation

Studies have shown that USP37 promotes cell migration by deubiquitinating and stabilizing the EMT-inducing transcription factor SNAI, suggesting a potential role in metastasis that warrants further investigation in appropriate model systems.

What are common challenges in Western blot detection of USP37 and how can they be resolved?

Western blot detection of USP37 presents several technical challenges that researchers frequently encounter. These issues can impact data quality and interpretation, but can be systematically addressed through optimization strategies.

Common challenges and troubleshooting approaches:

• High molecular weight detection issues:

  • Challenge: USP37's large size (110.2 kDa) can lead to inefficient transfer and detection.

  • Solutions:

    • Extend transfer time (1-2 hours) or use lower voltage overnight transfer

    • Use gradient gels (4-12%) for better resolution of high molecular weight proteins

    • Add 0.1% SDS to transfer buffer to improve high MW protein transfer

    • Reduce gel percentage to 7.5% for better resolution

• Multiple bands or smearing:

  • Challenge: Detection of multiple bands or smears rather than a clean single band.

  • Solutions:

    • Increase blocking stringency (5% BSA or milk, overnight at 4°C)

    • Add 0.1% Tween-20 to antibody dilution buffer

    • Use fresh protease and deubiquitinase inhibitors in lysis buffer

    • Consider that multiple bands may represent isoforms or post-translationally modified USP37

    • Verify band identity using knockout/knockdown controls

• Weak signal strength:

  • Challenge: Inadequate signal detection despite appropriate expression.

  • Solutions:

    • Increase antibody concentration (try 1:500 dilution)

    • Extend primary antibody incubation (overnight at 4°C)

    • Use signal enhancement systems (e.g., HRP substrates with extended signal duration)

    • Enrich samples through immunoprecipitation before Western blotting

    • Consider tissue-specific extraction protocols to enhance yield

• Inconsistent results across experiments:

  • Challenge: Variable detection between experimental replicates.

  • Solutions:

    • Standardize protein extraction and quantification protocols

    • Prepare larger batches of antibody dilutions to use across experiments

    • Include positive control lysates in each experiment

    • Consider cell cycle synchronization, as USP37 levels fluctuate during the cell cycle

A recommended Western blot protocol for USP37 detection includes using 7.5% gels, transferring at 30V overnight, blocking with 5% BSA in TBST, and incubating with primary antibody (1:1000 dilution) overnight at 4°C. This approach has been validated for detecting endogenous USP37 in human, mouse, rat, and Xenopus laevis samples.

How can researchers accurately interpret USP37 localization patterns in immunofluorescence studies?

Accurate interpretation of USP37 localization patterns in immunofluorescence studies requires careful attention to experimental design, appropriate controls, and consideration of USP37's dynamic localization in response to cellular conditions. USP37 exhibits complex localization patterns that shift based on cell cycle phase and DNA damage status.

Key considerations for immunofluorescence studies of USP37:

• Expected localization patterns:

  • Interphase cells: Predominantly nuclear with some cytoplasmic distribution

  • S-phase cells: Enhanced association with replication foci (co-localization with PCNA)

  • Mitotic cells: Redistribution to the mitotic spindle apparatus

  • After DNA damage: Accumulation at DNA damage sites (co-localization with γH2AX)

• Critical validation controls:

  • Antibody specificity controls (pre-absorption with immunizing peptide)

  • siRNA/shRNA knockdown to confirm signal specificity

  • Secondary antibody-only controls to assess background fluorescence

  • Co-staining with cell cycle markers to correlate localization with cell cycle phase

• Technical optimization recommendations:

  • Fixation method: 4% paraformaldehyde (10 minutes at room temperature) preserves USP37 localization

  • Permeabilization: 0.2% Triton X-100 (5 minutes) provides optimal nuclear access

  • Blocking: 3-5% BSA with 0.1% Tween-20 reduces non-specific binding

  • Antibody dilution: 1:100-1:200 typically provides optimal signal-to-noise ratio

• Advanced co-localization analyses:

  • Quantify co-localization with interaction partners (BLM, CHK1, WAPL) using Pearson's correlation coefficient

  • Perform sequential immunofluorescence to avoid cross-reactivity between antibodies

  • Use super-resolution microscopy (STED, STORM) for precise localization at replication foci or damage sites

• Dynamic localization studies:

  • Live-cell imaging with GFP-tagged USP37 to track real-time localization changes

  • Photobleaching techniques (FRAP) to assess USP37 mobility in different cellular compartments

  • Cell cycle synchronization to capture phase-specific localization patterns

When interpreting results, researchers should consider that USP37 localization is dynamic and sensitive to experimental conditions. Phosphorylation status, particularly ATM-mediated phosphorylation following DNA damage, significantly impacts USP37 localization and should be considered when designing and interpreting immunofluorescence experiments.

How do researchers reconcile contradictory findings about USP37 function in different experimental systems?

Reconciling contradictory findings about USP37 function across different experimental systems requires systematic analysis of experimental variables and biological contexts. Several factors can contribute to apparently contradictory results, and understanding these factors is essential for accurate data interpretation.

Strategies for addressing contradictory findings:

• Cell type-specific context analysis:

  • Approach: Compare USP37 expression levels, interacting partners, and substrate availability across cell types.

  • Method: Perform parallel experiments in multiple cell lines representing different tissues or disease states.

  • Interpretation: Different outcomes may reflect genuine biological differences rather than experimental artifacts.

• Experimental methodology differences:

  • Approach: Assess whether contradictions arise from methodological variations.

  • Method: Standardize key protocols (protein extraction, antibodies, detection methods) across laboratories.

  • Interpretation: Methodological differences in antibody specificity, knockdown efficiency, or assay sensitivity may explain contradictory findings.

• Cell cycle phase considerations:

  • Approach: Determine if contradictions relate to cell cycle-dependent functions.

  • Method: Synchronize cells and evaluate USP37 function at specific cell cycle phases.

  • Interpretation: USP37's phosphorylation and activity change dramatically during cell cycle progression, potentially explaining different outcomes in asynchronous populations.

• Genetic background variations:

  • Approach: Analyze genetic differences between experimental systems.

  • Method: Sequence USP37 and key regulatory genes across cell lines used in contradictory studies.

  • Interpretation: Genetic variants affecting USP37 regulation or substrate interaction may explain functional differences.

• Experimental perturbation strength:

  • Approach: Assess degree of USP37 manipulation across studies.

  • Method: Quantify knockdown/knockout efficiency or overexpression levels.

  • Interpretation: Partial versus complete depletion may reveal different aspects of USP37 function due to compensation mechanisms.

• Meta-analysis framework:

  • Approach: Systematically compare experimental conditions across studies.

  • Method: Create a structured comparison table highlighting key variables.

  • Interpretation: Identify patterns explaining when certain functions are observed versus others.

A comprehensive reconciliation approach combines:

• Replication of key experiments under standardized conditions

• Genetic rescue experiments to confirm specificity

• Detailed characterization of cell cycle status during experiments

• Assessment of USP37 phosphorylation state across experimental systems

For example, seemingly contradictory findings regarding USP37's role in cell proliferation might be reconciled by analyzing cell cycle distribution, as USP37's growth-promoting effects are most pronounced during G1/S transition but may be less evident in cells predominantly in other phases.

What emerging research directions are advancing our understanding of USP37 function?

Research on USP37 is rapidly evolving, with several emerging directions expanding our understanding of this multifunctional deubiquitinase. Current evidence establishes USP37's roles in cell cycle regulation, DNA replication, and DNA damage response, but new research frontiers are revealing additional functions and potential therapeutic applications.

Promising research directions include:

• Structural biology approaches: Recent advances in cryo-electron microscopy and X-ray crystallography are being applied to elucidate USP37's three-dimensional structure, particularly the catalytic domain and substrate-binding regions. These structural insights will inform the rational design of specific inhibitors.

• USP37 in stem cell biology: Preliminary evidence suggests USP37 may regulate pluripotency factors and differentiation pathways, representing an unexplored area that connects USP37 to developmental processes and regenerative medicine applications.

• Single-cell analysis of USP37 function: Application of single-cell technologies to track USP37 activity in heterogeneous cell populations may resolve contradictory findings by capturing cell-to-cell variability in USP37 expression and function.

• USP37 in immune regulation: Emerging data points to potential roles for USP37 in immune cell function and inflammatory signaling, expanding its relevance beyond cell cycle control and DNA damage response.

• Therapeutic targeting strategies: Development of selective USP37 inhibitors represents an active area of research, with potential applications in cancer therapy, particularly in tumors where USP37 is overexpressed or hyperactivated.

• USP37 in age-related diseases: Given its role in maintaining genomic stability, USP37 dysfunction may contribute to age-related pathologies, opening avenues for investigation in neurodegeneration and aging research.

• Post-translational modification crosstalk: Beyond phosphorylation, research is exploring how other modifications (acetylation, SUMOylation) may regulate USP37 activity, creating a complex regulatory network.

Future research will benefit from integrating multiple methodologies, including CRISPR screens to identify synthetic lethal interactions, proteomics to comprehensively map the USP37 interactome, and systems biology approaches to place USP37 within broader cellular signaling networks.